A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia
A. L. Smith, A. P. Eiken, D. Y. Moore, L. T. Umeta, L. M. Smith, E. R. Lyden, C. R. D'Angelo, A. Kallam, J. M. Vose, T. G. Kutateladze, D. El-Gamal
This study shows that SRX3305, a triple-action inhibitor targeting BTK, PI3K, and BRD4, reduces CLL cell proliferation, promotes apoptosis, and blocks migration in preclinical models.
bioRxiv · May 11, 2022Cancer Biology